Semantic inference using chemogenomics data for drug discovery

被引:10
|
作者
Zhu, Qian [1 ]
Sun, Yuyin [2 ]
Challa, Sashikiran [1 ]
Ding, Ying [2 ]
Lajiness, Michael S. [3 ]
Wild, David J. [1 ]
机构
[1] Indiana Univ, Sch Informat & Comp, Bloomington, IN 47408 USA
[2] Indiana Univ, Sch Lib & Informat Sci, Bloomington, IN 47408 USA
[3] Eli Lilly & Co, Indianapolis, IN 46225 USA
来源
BMC BIOINFORMATICS | 2011年 / 12卷
关键词
Clozapine; Resource Description Framework; Ergot Alkaloid; Methysergide; SPARQL Query;
D O I
10.1186/1471-2105-12-256
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: Semantic Web Technology (SWT) makes it possible to integrate and search the large volume of life science datasets in the public domain, as demonstrated by well-known linked data projects such as LODD, Bio2RDF, and Chem2Bio2RDF. Integration of these sets creates large networks of information. We have previously described a tool called WENDI for aggregating information pertaining to new chemical compounds, effectively creating evidence paths relating the compounds to genes, diseases and so on. In this paper we examine the utility of automatically inferring new compound-disease associations (and thus new links in the network) based on semantically marked-up versions of these evidence paths, rule-sets and inference engines. Results: Through the implementation of a semantic inference algorithm, rule set, Semantic Web methods (RDF, OWL and SPARQL) and new interfaces, we have created a new tool called Chemogenomic Explorer that uses networks of ontologically annotated RDF statements along with deductive reasoning tools to infer new associations between the query structure and genes and diseases from WENDI results. The tool then permits interactive clustering and filtering of these evidence paths. Conclusions: We present a new aggregate approach to inferring links between chemical compounds and diseases using semantic inference. This approach allows multiple evidence paths between compounds and diseases to be identified using a rule-set and semantically annotated data, and for these evidence paths to be clustered to show overall evidence linking the compound to a disease. We believe this is a powerful approach, because it allows compound-disease relationships to be ranked by the amount of evidence supporting them.
引用
下载
收藏
页数:12
相关论文
共 50 条
  • [1] Semantic inference using chemogenomics data for drug discovery
    Qian Zhu
    Yuyin Sun
    Sashikiran Challa
    Ying Ding
    Michael S Lajiness
    David J Wild
    BMC Bioinformatics, 12
  • [2] Chemogenomics in drug discovery
    Kubinyi, H.
    CHEMICAL GENOMICS: SMALL MOLECULE PROBES TO STUDY CELLULAR FUNCTION, 2006, 58 : 1 - 19
  • [3] Chemogenomics: drug discovery's panacea?
    Jacoby, Edgar
    MOLECULAR BIOSYSTEMS, 2006, 2 (05) : 218 - 220
  • [4] Chemical biology and chemogenomics in drug discovery
    Kubinyi, H.
    FEBS JOURNAL, 2007, 274 : 40 - 40
  • [5] Computational Chemogenomics in Drug Design and Discovery
    Bisson, William H.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2012, 12 (17) : 1867 - 1868
  • [6] Chemogenomics: Bridging a drug discovery gap
    Bleicher, KH
    CURRENT MEDICINAL CHEMISTRY, 2002, 9 (23) : 2077 - 2084
  • [7] Polypharmacological Drug-target Inference for Chemogenomics
    Schneider, Petra
    Schneider, Gisbert
    MOLECULAR INFORMATICS, 2018, 37 (9-10)
  • [8] Semantic Rules on Drug Discovery Data
    Challa, Sashikiran
    Wild, David
    Ding, Ying
    Zhu, Qian
    SEMANTIC WEB, PROCEEDINGS, 2009, 5926 : 362 - 364
  • [9] Chemogenomics: A novel information tool for drug discovery
    Browne, Leslie J.
    Squires, Douglas J.
    Nicholas, Judith A.
    Pharmaceutical Technology North America, 2002, 26 (07): : 84 - 86
  • [10] Cell biology, chemogenomics and chemoproteomics - application to drug discovery
    Gagna, Claude E.
    Lambert, W. Clark
    EXPERT OPINION ON DRUG DISCOVERY, 2007, 2 (03) : 381 - 401